Neurocrine Biosciences, Inc. (NBIX) stock analysis

In our weekly check, Neurocrine Biosciences, Inc. is graded A (A to F). Of 24 checks on debt, profit, cash flow and trend: 21 pass, warnings: 1, red flags: 2.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in the United States, listed on NASDAQ as NBIX.

What our checks show for NBIX

Red flags

• The stock has fallen as much as 86% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 3.6 years.

Warning signs

• Pay in shares equals 31.3% of free cash flow: it dilutes shareholders.

Strengths

• Net debt is only 0.1x a year of EBITDA: the balance sheet has room.
• Operating profit covers interest 272 times over.
• The net margin rose by 13 points over 5 years, to 20.9%.
• Analysts expect earnings per share to grow about 24.9% a year over the next years.
• Analysts expect revenue to grow about 17.4% a year over the next years.
• Analysts expect the net margin to improve by 11 points from today's 20.9%.

Next earnings report: 2026-11-02

Similar companies

HALO · JAZZ · ASND · BBIO · EXEL · SMMT

Questions

What grade does Neurocrine Biosciences, Inc. (NBIX) have?

In our weekly check, Neurocrine Biosciences, Inc. is graded A (A to F). Of 24 checks on debt, profit, cash flow and trend: 21 pass, warnings: 1, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of NBIX stock?

This week's biggest flags for Neurocrine Biosciences, Inc.: Deep past fall, Slow recovery after falls, Heavy stock pay. In total 3 of 24 checks show a warning or a red flag.

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in the United States, listed on NASDAQ as NBIX.

When does Neurocrine Biosciences, Inc. report earnings next?

The next earnings report is expected on 2026-11-02. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis